We are delighted to be the patient partner in a 4-year research programme funded through Horizon Europe, the European Union's framework program for research and innovation. “Therapies for Renal Ciliopathies” (TheRaCil) was in the call "Development of new effective therapies for rare diseases".

TheRaCiL brings together 16 partners - 15 institutions in 6 countries - 3 European consortia and the Ciliopathy Alliance with the ambition to develop appropriate and targeted treatments for paediatric renal ciliopathies. TheRaCil will benefit from a European Commission funding of 7,425,446 euros and a co-funding of 540,520 euros from UK Research and Innovation (UKRI). 

At the TheRaCiL 2026 Annual Meeting in Cologne, Fiona Copeland had the opportunity to represent the Ciliopathy Alliance to listen, learn and contribute as researchers, clinicians and patient representatives explored how early scientific discoveries might eventually lead to clinical studies that genuinely matter to patients.